1. Home
  2. PHVS vs UTL Comparison

PHVS vs UTL Comparison

Compare PHVS & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$36.02

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo UNITIL Corporation

UTL

UNITIL Corporation

HOLD

Current Price

$51.85

Market Cap

906.9M

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHVS
UTL
Founded
2015
1984
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Power Generation
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
906.9M
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
PHVS
UTL
Price
$36.02
$51.85
Analyst Decision
Buy
Buy
Analyst Count
11
2
Target Price
$41.82
$56.50
AVG Volume (30 Days)
1.0M
95.5K
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
3.65%
EPS Growth
N/A
1.37
EPS
N/A
2.11
Revenue
N/A
$536,000,000.00
Revenue This Year
N/A
$5.43
Revenue Next Year
N/A
$4.22
P/E Ratio
N/A
$24.54
Revenue Growth
N/A
8.33
52 Week Low
$20.65
$45.33
52 Week High
$43.25
$57.26

Technical Indicators

Market Signals
Indicator
PHVS
UTL
Relative Strength Index (RSI) 49.86 39.18
Support Level $32.77 $50.20
Resistance Level $36.80 $52.19
Average True Range (ATR) 2.10 1.03
MACD -0.11 -0.15
Stochastic Oscillator 27.78 22.40

Price Performance

Historical Comparison
PHVS
UTL

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

Share on Social Networks: